Results 1 to 10 of about 186,891 (292)
Rituximab Iodination Procedure for Radioiodinated Rituximab (131I-Rituximab) Preparation [PDF]
Majalah Kedokteran Bandung, 2019 Rituximab is a chimeric monoclonal antibody which has specific for CD20 antigen expressed by pre-B and mature B-cells. Radiolabelled Rituximab, 131I-Rituximab, has been sucessfully used for treatment of B-Cell NHL.
Martalena Ramli +4 more
doaj +2 more sources
Case series of low dose rituximab for membranous nephropathy; a single centre experience [PDF]
Journal of Nephropathology, 2023 Introduction: Rituximab is the recent treatment of choice for primary membranous nephropathy However, dose of rituximab mentioned in literature is high and not economical in middle income countries.
Gerry George Mathew +2 more
doaj +1 more source
Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients
Frontiers in Immunology, 2023 BackgroundBy depleting circulating B lymphocytes, rituximab time-dependently suppresses coronavirus disease 2019 (COVID-19) vaccines’ humoral immunogenicity for a prolonged period.
Chutima Seree-aphinan +9 more
doaj +1 more source
Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
Frontiers in Immunology, 2021 Primary membranous nephropathy (pMN) is an autoimmune kidney disease and a common cause of nephrotic syndrome in adults. Rituximab is becoming a first line therapy for patients with persistent nephrotic syndrome with proven safety and efficacy, achieving
Maxime Teisseyre +15 more
doaj +1 more source
RITUXIMAB-INDUCED SEVERE ACUTE THROMBOCYTOPENIA IN A PATIENT WITH SPLENIC MARGINAL ZONE LYMPHOMA
Hematology, Transfusion and Cell Therapy, 2022 Objective: Rituximab, which is widely used in the treatment of B-cell lymphoma, is a chimeric monoclonal antibody directed against the CD20 antigen. Rituximab has many side effects, mainly allergic and neurological.
Taha Ulutan Kars +3 more
doaj +1 more source
Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
Frontiers in Immunology, 2020 Membranous Nephropathy (MN) is an autoimmune disease associated with antibodies against podocyte proteins: M-type phospholipase A2 receptor (PLA2R1) or thrombospondin type-1 domain-containing 7A (THSD7A) in 70 and 3% of patients, respectively.
Sonia Boyer-Suavet +13 more
doaj +1 more source
Best Practice & Research Clinical Haematology, 2011 Rituximab has become a ubiquitous component of treatment regimens for follicular non-Hodgkin lymphoma. Despite widespread clinical use, the mechanisms by which tumor cells resist rituximab-mediated destruction remain unclear. Rituximab relies in part on immune effector mechanisms for its antitumor effect, and thus resistance may be mediated not only by
Andrew R, Rezvani, David G, Maloney
openaire +2 more sources
American Journal of Neuroradiology, 2010 Rituximab is a monoclonal antibody that was first approved by the FDA as an antineoplastic agent designed to treat B-cell malignancies. This article will review the mechanism of action and clinical role of this anti-B-cell agent.
David T, Selewski +4 more
openaire +2 more sources
Is it the time to offer rituximab as a cost-benefit treatment for immunoglobulin A nephropathy? A short-review to current concepts [PDF]
Journal of Nephropathology, 2018 Context: IgA nephropathy (IgAN) as an autoimmune disease is the most common cause of glomerulonephritis worldwide. Rituximab effectively depletes B cells and reduces serum levels of IgA1 antibodies.
Mohammad-Reza Tamadon +2 more
doaj +1 more source
Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E [PDF]
, 2020 Hepatitis E virus (HEV) infection is an emerging disease in industrialized countries which is usually characterized by a self-limited course. However, there is an increased risk of HEV persistence in immunocompromised risk populations, comprising ...
Biedermann, Paula +7 more
core +1 more source